Reposted by Sean Spencer
Today our team published additional results from the Phase 2 CONSORTIUM study for our lead candidate, VE303, a potential first-in-class Live Biotherapeutic Product which is being evaluated for prevention of recurrent Clostridioides difficile infection (rCDI).
full-text access: rdcu.be/d5ovX
rdcu.be
Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection
Nature Medicine - Results of multi-omic profiling of the microbiome and host immunity of individuals treated with VE303 to prevent recurrent Clostridioides difficile infection in the context of a...